This study enrolls people who have been diagnosed with Tricuspid Regurgitation (TR). The purpose of this study is to look at the safety and effectiveness of this new investigational device compared to the standard medical treatment. Read More
Adults ages 18+
Diagnosed with Tricuspid Regurgitation/Insufficiency
This study enrolls children and young adults with congenital anomalies of the kidney and urinary tract (CAKUT). The purpose of the study is to learn which gene mutation(s) may be responsible for this condition and to eventually find a gene therapy to treat this condition. Read More
Children and young adults ages 0-21 years old with CAKUT (congenital anomalies of the kidney and urinary tract) seen at Oshei Children's Hospital
Patient's family member without CAKUT.
This study enrolls adults who work in a pharmacy that is part of the Community Pharmacy Enhanced Services Network (CPESN). The purpose of this study is to learn about if it would be feasible to make a Community Heath Worker (CHW) program embedded within a pharmacy practice. Read More
Adults ages 18+.
Staff member in a pharmacy that is part of the Community Pharmacy Enhanced Services Network (CPESN) in New York and Missouri. Some of these pharmacies are implementing community health worker programs focused on patients with chronic health issues.
People eligible to participate in this study will be directly contacted by the study staff.
This study enrolls people with Congenital Adrenal Hyperplasia (CAH), a rare condition that changes the body’s ability to create key hormones. To replace these important hormones, people who live with CAH need to take constant doses of steroids, which mimic hormones and help the body function. The purpose of this study is to learn about how safe and effective a non-steroid option is to treat CAH. Read More
Adults ages 18-55
Has a diagnosis of Classic Congenital Adrenal Hyperplaysia due to 21-hydroxylase deficiency
You'll have been on a stable daily dose of steroids (glucocorticoids or mineralocorticoid) before starting the trial.
Please contact the study team for additional eligibility criteria.
This study enrolls healthy adults who will be getting a vaccine. The goal of this study is to learn about immune system cells called macrophages. Macrophages are important immune system cells that form when an infection is in the body. Read More
Adults ages 20-55.
Scheduled to receive a vaccine, like the COVID-19 or flu vaccine (for COVID-19 vaccine, study must be done before and after the first dose of the vaccine).
This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer. Read More
Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.
This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More
Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).
This study enrolls children who are having orthodontic treatment and need a rapid maxillary expansion (RME) device. The purpose of this study is to learn about the effects of palatal expansion on jaw movement during sleep. Read More
-Children ages 7-14.
-Are under orthodontic care and need to use a rapid maxillary expansion (RME) device
This study enrolls people who have mitral regurgitation (MR). Mitral regurgitation happens when the heart’s mitral valve does not close tightly. The purpose of this trial is to evaluate a new investigational device called the Tendyne™ Mitral Valve System. The Tendyne Mitral Valve System is designed for the treatment of a diseased, damaged or malfunctioning mitral valve. This trial will collect information on how safe and effective this device is to treat a leaking mitral valve compared to the commercially available MitraClip® System. Read More
-Adults ages 18+.
-Have symptomatic, moderate-to-severe/severe mitral regurgitation (MR) or severe mitral annular calcification (MAC)
-Your medical providers have decided a transcatheter therapy is more appropriate than open surgery.